Program
tonlamarsen
Also written as “Tonlamarsen” and “ION904”.
Its studies are mostly in Hypertension · Hypertensive Crisis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ionis Pharmaceuticals | 20 open or running | phase 2since Mar 29, 2022 | Jan 26, 2021 | none ahead |
| Kardigan | 21 open or running | phase 2since Feb 12, 2025 | Feb 12, 2025 | Dec 2026phase 2 · NCT07511361 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2021First study: phase 1 study in HypertensionNew to Ionis PharmaceuticalsIonis Pharmaceuticals · NCT04731623 · 40 enrolled · Canada
- Mar 29, 2022Phase 2 study in HypertensionIonis Pharmaceuticals · NCT05314439 · 48 enrolled · United States
- Feb 12, 2025Kardigan's first study: phase 2 study in HypertensionNew to KardiganKardigan · NCT06864104 · 206 enrolled · United States
- Mar 28, 2026Phase 2 study in HypertensionKardigan · NCT07511361 · 140 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in HypertensionKardigan · NCT07511361
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07511361Hypertension · United States | 2 | Recruiting | Kardigan | Dec 2026 | 140 |
| NCT06864104Hypertension · United States | 2 | Completed | Kardigan | Jan 12, 2026 | 206 |
| NCT05314439Hypertension · United States | 2 | Completed | Ionis Pharmaceuticals | Jan 31, 2023 | 48 |
| NCT04731623Hypertension · Canada | 1 | Completed | Ionis Pharmaceuticals | Aug 12, 2021 | 40 |
How it is read
Names in the registry
- “Tonlamarsen”, 2 entries
- “ION904”, 2 entries
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Hypertensive Crisis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.